NICE has published guidance (TA238) recommending tocilizumab for the treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease has responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and methotrexate if the manufacturer makes tocilizumab available with the discount agreed as part of the patient access scheme.

Tocilizumab is not recommended for the treatment of systemic juvenile
idiopathic arthritis in children and young people aged 2 years and older whose
disease continues to respond to methotrexate or who have not been treated
with methotrexate.

Children and young people currently receiving tocilizumab for the treatment of
systemic juvenile idiopathic arthritis who do not meet the above criteria should
have the option to continue treatment until it is considered appropriate to stop.
This decision should be made jointly by the clinicians, and the child or young
person and/or their parents or carers.